Dementia Diagnostics Market
完整報告名稱與涵蓋範圍
Dementia Diagnostics Market Size, Share & Trends Analysis Report, By Diagnostic Type (Cognitive Assessment, Neuroimaging, Biomarker & Blood-Based Testing, Digital Screening Tools), By Disease Type (Alzheimer's Disease, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia, Other Dementias), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
Dementia diagnostics spans the tools used to detect, differentiate and stage cognitive disorders, including structured cognitive assessment batteries, neuroimaging with MRI and amyloid or tau PET tracers, cerebrospinal fluid and blood-based biomarker assays measuring amyloid-beta and phosphorylated tau species, and digital screening platforms that capture speech, drawing and reaction-time signals in primary care or at home.
The market's defining catalyst is the arrival of disease-modifying anti-amyloid therapies for early Alzheimer's disease, which for the first time make biological confirmation of amyloid pathology a gateway to treatment rather than an academic exercise. Because PET capacity and lumbar puncture tolerance cannot triage entire ageing populations, plasma assays, particularly phosphorylated tau markers on high-sensitivity immunoassay platforms, are moving into routine laboratory menus as front-line rule-in and rule-out tools. Upstream, health systems face pressure to shorten the multi-year interval between first symptoms and specialist diagnosis, which is pulling brief digital cognitive tests into primary care workflows and annual wellness visits. Differential diagnosis across Alzheimer's, vascular, Lewy body and frontotemporal aetiologies sustains demand for multimodal work-ups.
North America leads through early therapy adoption, established PET reimbursement and reference-laboratory scale, with Europe following as national appraisal bodies define testing pathways and Japan an early Asia Pacific adopter alongside rapidly ageing China. Competitively, the field combines large in vitro diagnostics and imaging companies with specialised biomarker laboratories, radiopharmaceutical developers and digital assessment start-ups, and remains far from consolidated.
The InsightAce study delivers revenue forecasts in US$ across all segments and regions for 2026-2035, segment-level trend analysis, competitive landscape assessment and company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Dementia Diagnostics Market Snapshot
Chapter 4. Global Dementia Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Diagnostic Type Estimates & Trend Analysis
5.1. Diagnostic Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Diagnostic Type:
5.2.1. Cognitive Assessment
5.2.2. Neuroimaging
5.2.3. Biomarker & Blood-Based Testing
5.2.4. Digital Screening Tools
Chapter 6. Market Segmentation 2: By Disease Type Estimates & Trend Analysis
6.1. Disease Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Disease Type:
6.2.1. Alzheimer's Disease
6.2.2. Vascular Dementia
6.2.3. Lewy Body Dementia
6.2.4. Frontotemporal Dementia
6.2.5. Other Dementias
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Hospitals & Memory Clinics
7.2.2. Diagnostic Laboratories
7.2.3. Imaging Centers
7.2.4. Academic & Research Institutes
Chapter 8. Dementia Diagnostics Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Roche Diagnostics
10.2. Fujirebio
10.3. C2N Diagnostics
10.4. Quanterix
10.5. Eli Lilly (Avid Radiopharmaceuticals)
10.6. GE HealthCare
10.7. Life Molecular Imaging
10.8. Siemens Healthineers
10.9. Quest Diagnostics
10.10. Labcorp
10.11. Cogstate
10.12. Linus Health
10.13. Altoida
10.14. Cambridge Cognition
圖表清單 List of Tables & Figures
Table 1. Global Dementia Diagnostics Revenue Forecast by Diagnostic Type, 2026-2035 (US$ Mn)
Figure 1. Dementia Diagnostic Pathway: Screening to Biological Confirmation
Table 2. Global Dementia Diagnostics Revenue Forecast by Disease Type, 2026-2035 (US$ Mn)
Figure 2. Global Dementia Diagnostics Share by Diagnostic Type, 2026 & 2035
Table 3. Global Dementia Diagnostics Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Blood-Based Biomarker Adoption Curve versus PET and CSF Testing
Table 4. North America Dementia Diagnostics Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Impact of Disease-Modifying Therapy Launches on Diagnostic Volumes
Table 5. Europe Dementia Diagnostics Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Amyloid and Tau PET Tracer Availability by Region
Table 6. Asia Pacific Dementia Diagnostics Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Dementia Diagnostics Growth Opportunity Analysis
Table 7. Latin America and Middle East & Africa Dementia Diagnostics Revenue, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Dementia Diagnostics Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們